Heterocyclic compound classes for signaling modulation
US10174032B2 · kind B2 · utility
4Cited by
3References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 2015 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | May 31, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to compounds of Formulas I-VII (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating cellular signaling pathways and biological processes associated therewith including inhibition of kinase activity such as PI-3 kinase or inhibition of bromodomain proteins or both at the same time as well as to therapeutic methods for treating a disease associated with aberrant PI3K and/or bromodomain proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.